Ian Mortimer Xenon Pharmaceuticals Inc. (XENE) insider trading activity

XENE Quotes by TradingView

Ian Mortimer is PRESIDENT & CEO of Xenon Pharmaceuticals Inc.. Currently has a direct ownership of 6,000 shares of XENE, which is worth approximately $244,560. The most recent transaction as insider was on Dec 08, 2025, when has been sold 10,830 shares (Common Shares) at a price of $45.96 per share, resulting in proceeds of $497,746. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6K
80.83% 3M change
80.83% 12M change
Total Value Held $244,560

IAN MORTIMER Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 08 2025
SELL
Open market or private sale
$497,746 $45.96 p/Share
10,830 Reduced 64.35%
6,000 Common Shares
Dec 05 2025
SELL
Open market or private sale
$647,306 $45.03 p/Share
14,375 Reduced 46.07%
16,830 Common Shares
Nov 28 2025
SELL
Open market or private sale
$4,365 $45.01 p/Share
97 Reduced 0.31%
31,205 Common Shares
Oct 01 2025
SELL
Open market or private sale
$1,003,999 $40.16 p/Share
25,000 Reduced 44.4%
31,302 Common Shares
Oct 01 2025
BUY
Exercise of conversion of derivative security
$192,250 $7.69 p/Share
25,000 Added 30.75%
56,302 Common Shares
Jan 27 2025
SELL
Open market or private sale
$664,999 $40.76 p/Share
16,315 Reduced 34.26%
31,302 Common Shares
Jan 27 2025
BUY
Exercise of conversion of derivative security
$289,754 $17.76 p/Share
16,315 Added 33.46%
32,451 Common Shares
Jan 24 2025
SELL
Open market or private sale
$903,213 $40.2 p/Share
22,468 Reduced 41.79%
31,302 Common Shares
Jan 24 2025
BUY
Exercise of conversion of derivative security
$399,031 $17.76 p/Share
22,468 Added 29.47%
53,770 Common Shares
Jan 23 2025
SELL
Open market or private sale
$649,977 $40.08 p/Share
16,217 Reduced 34.13%
31,302 Common Shares
Jan 23 2025
BUY
Exercise of conversion of derivative security
$288,013 $17.76 p/Share
16,217 Added 25.44%
47,519 Common Shares
May 24 2023
SELL
Open market or private sale
$1,311,466 $41.43 p/Share
31,655 Reduced 50.28%
31,302 Common Shares
May 24 2023
SELL
Payment of exercise price or tax liability
$518,104 $41.84 p/Share
12,383 Reduced 27.46%
32,709 Common Shares
May 24 2023
BUY
Exercise of conversion of derivative security
$673,291 $9.71 p/Share
69,340 Added 67.18%
33,880 Common Shares
IM

Ian Mortimer

PRESIDENT & CEO
Burnaby, A1

Track Institutional and Insider Activities on XENE

Follow Xenon Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XENE shares.

Notify only if

Insider Trading

Get notified when an Xenon Pharmaceuticals Inc. insider buys or sells XENE shares.

Notify only if

News

Receive news related to Xenon Pharmaceuticals Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on XENE